上海2026年9月8日 /美通社/ -- 9月8日,新桥生物(纳斯达克股票代码:NBP,下称"新桥生物"或"公司"),一家专注于识别差异化创新,并采用严谨的开发、融资与合作策略以创造价值的全球生物技术公司,今日宣布,任命Martin Dewhurst先生为董事会独立董事,同时担任审计委员会及薪酬委员会成员,即时生效。 作为医疗健康领域全球领袖,Dewhurst先生在生物技术、生物制药、医疗器械、...
Source Link上海2026年9月8日 /美通社/ -- 9月8日,新桥生物(纳斯达克股票代码:NBP,下称"新桥生物"或"公司"),一家专注于识别差异化创新,并采用严谨的开发、融资与合作策略以创造价值的全球生物技术公司,今日宣布,任命Martin Dewhurst先生为董事会独立董事,同时担任审计委员会及薪酬委员会成员,即时生效。 作为医疗健康领域全球领袖,Dewhurst先生在生物技术、生物制药、医疗器械、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.